Marco Rosetti
Impact in
- Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology
-
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
Papers in
-
- Cancer therapeutics and mechanisms 5
- Oncology 9
- Cancer-related Molecular Pathways 3
- HER2/EGFR in Cancer Research 2
- Co-authors
- Wainer Zoli (18 shared papers)Anna Tesei (18 shared papers)Francesco� Fabbri (15 shared papers)Paola Ulivi (13 shared papers)Dino Amadori (10 shared papers)Ivan Vannini (11 shared papers)Giovanni Brigliadori (9 shared papers)Manlio Bolla (6 shared papers)
- Journals
- Journal of Cellular Physiology (3 papers)Journal of Translational Medicine (2 papers)APOPTOSIS (2 papers)Molecular Cancer Therapeutics (1 paper)British Journal of Haematology (1 paper)
- Partner nations
- ItalyIndiaUnited States
In The Last Decade
Marco Rosetti
23 papers receiving 475 citations
Peers
Comparison fields: 5 of 82
- Biochemistry 61
- Cancer Research 100
- Oncology 141
- Pharmacology 86
- Toxicology 12
Countries citing papers authored by Marco Rosetti
This map shows the geographic impact of Marco Rosetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Rosetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Rosetti more than expected).
Fields of papers citing papers by Marco Rosetti
This network shows the impact of papers produced by Marco Rosetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Rosetti. The network helps show where Marco Rosetti may publish in the future.
Co-authors
The 25 scholars most cited alongside Marco Rosetti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 73 | |
| 2 | 2005 | 59 | |
| 3 | 2008 | 51 | |
| 4 | 2009 | 29 | |
| 5 | 2005 | 29 | |
| 6 | 2005 | 28 | |
| 7 | Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. | 2006 | 28 |
| 8 | 2006 | 27 | |
| 9 | 2006 | 26 | |
| 10 | 2008 | 23 | |
| 11 | 2007 | 22 | |
| 12 | 2007 | 19 | |
| 13 | 2008 | 18 | |
| 14 | 2005 | 14 | |
| 15 | 2005 | 10 | |
| 16 | Pro-apoptotic activity of cyclopentenone in cancer cells. | 2008 | 10 |
| 17 | 2007 | 9 | |
| 18 | 2012 | 5 | |
| 19 | 1987 | 2 | |
| 20 | 2021 | 1 |
About Marco Rosetti
Marco Rosetti is a scholar working on Molecular Biology, Oncology, Pharmacology, Psychiatry and Mental health and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 486 indexed citations. Recurring topics across this work include Cancer, Stress, Anesthesia, and Immune Response (6 papers), Inflammatory mediators and NSAID effects (6 papers), Cancer therapeutics and mechanisms (5 papers), Bioactive Compounds and Antitumor Agents (3 papers), Cancer-related Molecular Pathways (3 papers), Eicosanoids and Hypertension Pharmacology (3 papers), Clinical Laboratory Practices and Quality Control (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Biochemistry (61 citations), Cancer Research (100 citations), Oncology (141 citations), Pharmacology (86 citations) and Toxicology (12 citations). Marco Rosetti has collaborated with scholars based in Italy, India and United States. Frequent co-authors include Wainer Zoli, Anna Tesei, Francesco� Fabbri, Paola Ulivi, Dino Amadori, Ivan Vannini, Giovanni Brigliadori, Manlio Bolla, Luca Ricotti and Carlo Leonetti. Their work appears in journals such as Journal of Cellular Physiology, Journal of Translational Medicine, APOPTOSIS, Molecular Cancer Therapeutics and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.